2D-LROC for 3D high-resolution structural analysis
2D-LROC for 3D high-resolution structural analysis
2D-LROC for 2D nanoscale optical imaging and functional screening
2D-LROC for 2D nanoscale optical imaging and functional screening
2D-LROC for 2D nanoscale optical imaging and functional screening
Advanced robotics and photonics design & engineering
News
Novatarg will be presenting at the 10th Annual Discovery on Target, on Wednesday October 3rd, at 12:10 pm.
Novatarg Pharmaceuticals secures patent for 2D-LROC advances.
Awards
The 2011French-American Accelerator for Innovative Startups Young Entrepreneurs Initiative (YEi) award.
Funding for 2D-LROC was provided in part by Small Business Innovation Research (SBIR) awards from the National Science Foundation and the National Institutes of Health.
Thirteen of fifteen world best-selling drugs target a membrane protein!
Soluble/UnidentifiedTargets
$12.49
12%
Transporters
$7.93
7%
Other Single-pass Membrane
Proteins
$13.48
12%
GPCRs
$43.75
$40%
Receptor
Tyrosine Kinases
$5.48
5%
Other Multi-pass Membrane Proteins
$26.13
24%
Global 2011 sales in $billion
Membrane proteins are the largest class of drug targets. The market for drugs targeting membrane proteins is estimated to exceed $500 billion. Yet the dependence of membrane proteins on lipids, together with their lack of solubility in water has rendered a challenge to characterization of their structure which is indispensable to modern structure-guided drug design. Conventional solution-based techniques often fail, or produce unreliable, inconsistent, or insufficient structural information for membrane proteins.
Novatarg designs and creates the revolutionary Membrane Protein 2D-LROC advances to support and develop key applications in targeted therapies, molecular diagnostics, and consumer products.
